Annual ROE
-14.01%
+18.51%+56.92%
December 31, 2023
Summary
- As of February 7, 2025, DNLI annual return on equity is -14.01%, with the most recent change of +18.51% (+56.92%) on December 31, 2023.
- During the last 3 years, DNLI annual ROE has fallen by -23.22% (-252.12%).
- DNLI annual ROE is now -113.05% below its all-time high of 107.38%, reached on December 31, 2015.
Performance
DNLI ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly ROE
-32.93%
+0.70%+2.08%
September 30, 2024
Summary
- As of February 7, 2025, DNLI quarterly return on equity is -32.93%, with the most recent change of +0.70% (+2.08%) on September 30, 2024.
- Over the past year, DNLI quarterly ROE has increased by +0.70% (+2.08%).
- DNLI quarterly ROE is now -149.36% below its all-time high of 66.71%, reached on June 30, 2017.
Performance
DNLI Quarterly ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
ROE Formula
ROE = Net Income
Shareholders Equity ✕ 100%
Shareholders Equity ✕ 100%
DNLI ROE Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +56.9% | +2.1% |
| 3 y3 years | -252.1% | +6.7% |
| 5 y5 years | -95.7% | +6.7% |
DNLI ROE Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +56.9% | -187.3% | +17.8% |
| 5 y | 5-year | -252.1% | +66.6% | -421.9% | +28.1% |
| alltime | all time | -113.0% | +66.6% | -149.4% | +80.8% |
Denali Therapeutics ROE History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | -32.93%(-2.1%) |
| Jun 2024 | - | -33.63%(+193.5%) |
| Mar 2024 | - | -11.46%(-15.1%) |
| Dec 2023 | -14.01%(-56.9%) | -13.50%(+11.2%) |
| Sep 2023 | - | -12.14%(-7.5%) |
| Jun 2023 | - | -13.12%(-67.3%) |
| Mar 2023 | - | -40.08%(+13.6%) |
| Dec 2022 | -32.52%(+18.2%) | -35.29%(+7.0%) |
| Sep 2022 | - | -32.97%(+12.6%) |
| Jun 2022 | - | -29.27%(+3.9%) |
| Mar 2022 | - | -28.18%(+2.8%) |
| Dec 2021 | -27.51%(-398.7%) | -27.40%(-1068.2%) |
| Sep 2021 | - | 2.83%(-52.3%) |
| Jun 2021 | - | 5.93%(-14.2%) |
| Mar 2021 | - | 6.91%(-32.5%) |
| Dec 2020 | 9.21% | 10.23%(-124.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2020 | - | -41.22%(-10.0%) |
| Jun 2020 | - | -45.80%(+0.8%) |
| Mar 2020 | - | -45.44%(+9.1%) |
| Dec 2019 | -41.97%(+486.2%) | -41.66%(+207.5%) |
| Sep 2019 | - | -13.55%(+22.3%) |
| Jun 2019 | - | -11.08%(+9.8%) |
| Mar 2019 | - | -10.09%(+39.4%) |
| Dec 2018 | -7.16%(-62.2%) | -7.24%(-74.1%) |
| Sep 2018 | - | -27.94%(-4.2%) |
| Jun 2018 | - | -29.17%(+28.7%) |
| Mar 2018 | - | -22.67%(-15.3%) |
| Dec 2017 | -18.93%(-120.6%) | -26.77%(-84.3%) |
| Sep 2017 | - | -171.04%(-356.4%) |
| Jun 2017 | - | 66.71%(+54.4%) |
| Mar 2017 | - | 43.20%(+110.1%) |
| Dec 2016 | 92.03%(-14.3%) | 20.56% |
| Dec 2015 | 107.38% | - |
FAQ
- What is Denali Therapeutics annual return on equity?
- What is the all time high annual ROE for Denali Therapeutics?
- What is Denali Therapeutics annual ROE year-on-year change?
- What is Denali Therapeutics quarterly return on equity?
- What is the all time high quarterly ROE for Denali Therapeutics?
- What is Denali Therapeutics quarterly ROE year-on-year change?
What is Denali Therapeutics annual return on equity?
The current annual ROE of DNLI is -14.01%
What is the all time high annual ROE for Denali Therapeutics?
Denali Therapeutics all-time high annual return on equity is 107.38%
What is Denali Therapeutics annual ROE year-on-year change?
Over the past year, DNLI annual return on equity has changed by +18.51% (+56.92%)
What is Denali Therapeutics quarterly return on equity?
The current quarterly ROE of DNLI is -32.93%
What is the all time high quarterly ROE for Denali Therapeutics?
Denali Therapeutics all-time high quarterly return on equity is 66.71%
What is Denali Therapeutics quarterly ROE year-on-year change?
Over the past year, DNLI quarterly return on equity has changed by +0.70% (+2.08%)